BMO Capital Initiates Coverage On Blueprint Medicines with Market Perform Rating, Announces $74 Price Target

BMO Capital analyst George Farmer initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Market Perform rating and a $74 price target.

Benzinga · 01/28/2020 11:30

BMO Capital analyst George Farmer initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Market Perform rating and a $74 price target.